Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11260086rdf:typepubmed:Citationlld:pubmed
pubmed-article:11260086lifeskim:mentionsumls-concept:C0013018lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C0337810lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C1504389lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C0015625lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C0596545lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C0445223lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C1552617lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C0282443lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C1552599lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C1704787lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C1514923lld:lifeskim
pubmed-article:11260086lifeskim:mentionsumls-concept:C0439743lld:lifeskim
pubmed-article:11260086pubmed:issue3lld:pubmed
pubmed-article:11260086pubmed:dateCreated2001-3-22lld:pubmed
pubmed-article:11260086pubmed:abstractTextTwenty-seven consecutive Italian patients with Fanconi's anaemia (FA) underwent stem cell transplantation (SCT) from an HLA-matched related donor in 10 Italian centres of the Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP), Gruppo Italiano di Trapianto di Midollo Osseo (GITMO). Twenty-two patients (81.5%) were conditioned with low-dose (median 20 mg/kg) cyclophosphamide (Cy) and thoraco-abdominal or total body irradiation (median dose 500 cGy), five patients (18.5%) with high-dose Cy (median 120 mg/kg). Graft-vs.-host disease (GVHD) prophylaxis was carried out with cyclosporin A in 26 cases; methotrexate (MTX) was added in eight cases. One patient received MTX alone. The median follow-up was 36 months. Ninety-two percent of patients (25 out of 27) engrafted, grade II and III acute GVHD occurred in 28% and 8% of patients, respectively, with chronic GVHD in 12.5%. Conditioning-related toxicity was mild: 4% of patients had grade III mucositis, 7.4% had grade II haemorrhagic cystitis, 14.8% had grade III liver toxicity and 11.1% had grade III renal toxicity. Transplant-related mortality at 12 months was 19.2%, survival at 36 months was 81.5%, with a median Karnofsky score of 100%. No late tumours occurred after a mean follow-up of the survivors of 5 years. None of the studied variables significantly affected the survival, including conditioning regimen, acute GVHD and clinical non-haematological phenotype. Among the studied variables, only conditioning regimens containing high-dose Cy and the presence of genital abnormalities were significantly (P < 0.05) associated with an increased rate of acute GVHD. Our study demonstrates that the Italian FA patients undergoing SCT from an HLA-matched related donor have a very good outcome. These patients, when compared with others of different ethnic origin who underwent allogeneic bone marrow transplantation, showed a less severe non-haematological phenotype, raising the possibility that this milder phenotype may have, at least in part, contributed to the outcome. Our data may provide a useful tool for further studies aiming to correlate genotype with phenotype.lld:pubmed
pubmed-article:11260086pubmed:languageenglld:pubmed
pubmed-article:11260086pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11260086pubmed:citationSubsetIMlld:pubmed
pubmed-article:11260086pubmed:statusMEDLINElld:pubmed
pubmed-article:11260086pubmed:monthMarlld:pubmed
pubmed-article:11260086pubmed:issn0007-1048lld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:BacigalupoAAlld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:DufourCClld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:LocatelliFFlld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:MadonEElld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:MessinaCClld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:PortaFFlld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:Di...lld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:Di GirolamoGGlld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:DiniGGlld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:PessionAAlld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:BalduzziAAlld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:RondelliRRlld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:MianoMMlld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:BukerGGlld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:IorioA PAPlld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:Associazione...lld:pubmed
pubmed-article:11260086pubmed:authorpubmed-author:Gruppo...lld:pubmed
pubmed-article:11260086pubmed:issnTypePrintlld:pubmed
pubmed-article:11260086pubmed:volume112lld:pubmed
pubmed-article:11260086pubmed:ownerNLMlld:pubmed
pubmed-article:11260086pubmed:authorsCompleteYlld:pubmed
pubmed-article:11260086pubmed:pagination796-805lld:pubmed
pubmed-article:11260086pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:meshHeadingpubmed-meshheading:11260086...lld:pubmed
pubmed-article:11260086pubmed:year2001lld:pubmed
pubmed-article:11260086pubmed:articleTitleStem cell transplantation from HLA-matched related donor for Fanconi's anaemia: a retrospective review of the multicentric Italian experience on behalf of AIEOP-GITMO.lld:pubmed
pubmed-article:11260086pubmed:affiliationDepartment of Paediatric Haematology-Oncology and BMT Unit, IRCCS G. Gaslini, Largo G. Gaslini 5, 16148 Genoa, Italy. carlodufour@ospedale-gaslini.ge.itlld:pubmed
pubmed-article:11260086pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11260086pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11260086pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11260086lld:pubmed